MissionIRNewsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Announces Class 3 EVs Begin Shipping

 Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has delivered the first 10 class 3 EV Cab Chassis Truck to Randy Marion Automotive Group; the vehicles are invoiced at $630,000. According to the announcement, these first 10 vehicles are the initial shipment of an order for 1,000 class 3 vehicles, an order worth $63 million; the order was placed in May 2023. The company anticipates delivering an additional 150 EVs to Randy Marion by the end of 2023, with the remainder of the 1,000-vehicle order slated for delivery throughout 2024. Calling the delivery a “watershed moment” for the company, the announcement noted that the Mullen THREE class 3 EV truck was the first vehicle produced, assembled and now delivered by the company. The Mullen THREE is produced in the company’s Tunica, Mississippi, facility, which houses Mullen’s commercial vehicle assembly for both Class 1 EV Cargo Vans and Class 3 EV Cab Chassis Trucks. “This is a significant point in our evolution as we shift the company from engineering development and engineering approvals to production and vehicle deliveries for our customers,” said Mullen CEO and chair David Michery in the press release. “As the Class 3 line is fully operational, production will be increasing month-to-month throughout the next year.”

To view the full press release, visit https://ibn.fm/kAXP6

About Mullen Automotive Inc.

Mullen Automotive is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover; the Mullen I-GO Commercial Urban Delivery EV; the Mullen commercial class 1–3 EVs; and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and class 4–6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of all Electric Last Mile Solutions (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. To learn more about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) Investigational Drug Focus of Study Published in Peer-Reviewed Journal

 Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis, announced the publication of a scientific paper. The paper, which was published in the “Small” journal, describes the catalytic mechanism of action of CLNN’s investigational drug CNM-Au8(R). “Small” is a leading nanotechnology-focused journal focused on the interface of materials from science, chemistry, physics, engineering, medicine and biology. Titled “A Mechanism Underpinning the Bioenergetic Metabolism-Regulating Function of Gold Nanocatalysts,” the article examines the potential for the novel catalytic mechanism of CNM-Au8 as a versatile new treatment to address multiple assaults on neuronal health in neurodegenerative diseases. The article is coauthored by lead investigators at the University of South Carolina and Clene.

According to the announcement, this study suggested that the robust neuroprotective properties of CNM-Au8 can be attributed to its therapeutic catalytic activity. The study was conducted by Hui Wang, PhD., a professor at the University of South Carolina, and a group of graduate students. “CNM-Au8 represents a new way to address the multiple assaults on neuronal health that occur during the course of neurodegenerative diseases,” said Clene vice president of translational medicine and study coauthor Karen S. Ho, PhD, in the press release. “Its catalytic activity strikes at a core metabolic deficiency and enables neurons to survive and function in a challenging environment that would otherwise lead to cell death. The remarkable promise of CNM-Au8 to address multiple different neurodegenerative diseases using this catalytic mechanism is truly exciting.”

To view the full press release, visit https://ibn.fm/50j6r

About Clene Inc.

Clene and its wholly owned subsidiary, Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is a federally registered trademark of Clene Nanomedicine Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

MissionIRNewsBreaks – Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) Begins Iska Iska Preliminary Economic Assessment

 Eloro Resources (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine-development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec, has started a preliminary economic assessment (“PEA”) for the Iska Iska silver-tin polymetallic project in the Potosi Department of southwestern Bolivia. According to the company, the PEA will study the inferred mineral resource estimate (“MRE”) of 560 million tonnes grading 13.8 g Ag/t, 0.73% Zn and 0.28% Pb in the Polymetallic (Ag-Zn-Pb) Domain and 110 million tonnes grading 0.12% Sn, 14.2 g Ag/t and 0.14% Pb in the Tin Domain (Sn-Ag-Pb). The announcement noted that for the purposes of the PEA, the mineral resources of both domains will be combined although they do not overlap or share resource blocks. Lead consultant for the assessment will be Australia-based Lycopodium, which will provide coordinate the PEA with development of metallurgical flowsheets. The PEA study will include design of tailings and waste dump facilities, mine design and infrastructure, environmental and hydrology studies.

“We are delighted to commence the PEA study on Iska Iska just three years after we began our initial exploration drill program,” said Eloro Resources CEO Tom Larsen in the press release. “This is another major step in moving the development of Iska Iska forward. We are also planning additional definition drilling to further expand the higher-grade zones as well as planning to carry out definitive ‘ore-sorting; tests at TOMRA in Germany. We have assembled an excellent team, which has already been onsite this week to kick off preparations for the PEA study. Recent induced polarization/resistivity surveys west of Santa Barbara have outlined several promising drill targets to extend the Tin Domain and initial drill testing is planned on these new targets.”

To view the full press release, visit https://ibn.fm/OxjF5

About Eloro Resources Ltd.

Eloro is an exploration and mine-development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec. Through its Bolivian subsidiary, Eloro has an option to acquire a 100% interest in the highly prospective Iska Iska Property, which can be classified as a polymetallic epithermal-porphyry complex, a significant mineral deposit type in the Potosi Department in southern Bolivia. A recent NI 43-101 technical report on Iska Iska, which was completed by Micon International Limited, is available on Eloro’s website and under its filings on SEDAR. Iska Iska is a road-accessible, royalty-free property. Eloro also owns an 82% interest in the La Victoria Gold/Silver Project, located in the north-central mineral belt of Peru, some 50 kilometers south of Barrick’s Lagunas Norte Gold Mine and Pan American Silver’s La Arena Gold Mine.

NOTE TO INVESTORS: The latest news and updates relating to ELRRF are available in the company’s newsroom at https://ibn.fm/ELRRF

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

RVL Pharmaceuticals plc (NASDAQ: RVLP) Presents Achievements, Goals at H.C. Wainwright 25th Annual Global Investment Conference in New York City

 

• RVL Pharmaceuticals CEO Brian Markison participated in a fireside chat and hosted one-on-one investor meetings during the conference
• The company’s primary focus is the commercialization of UPNEEQ(R), which is available by prescription for treating acquired blepharoptosis or low-lying eyelids in adults
• The global medical aesthetics market was estimated at $13.9 billion in 2022 and is expected to reach $23.4 billion by 2027, growing at a CAGR of 11%
• RVL Pharmaceuticals markets UPNEEQ(R) to HCPs and plans to launch a direct-to-consumer campaign later this year

RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas, recently presented at the H.C. Wainwright 25th Annual Global Investment Conference. The conference was held virtually and in person on September 11-13, 2023, at the Lotte New York Palace Hotel in New York City.

The H.C. Wainwright 25th Annual Global Investment Conference is the premier event for companies and investors in life sciences, cryptocurrency, blockchain, fintech, metals, mining, technology, media, telecommunications, cleantech, and more. The three-day event was filled with leading industry keynote speakers, presenting companies, investor one-on-one meetings, networking opportunities, and evening entertainment.

RVL Pharmaceuticals CEO Brian Markison participated in a fireside chat and hosted one-on-one investor meetings during this year’s H.C. Wainwright conference. The company’s primary focus is the commercialization of UPNEEQ(R), which is available by prescription for treating acquired blepharoptosis or low-lying eyelids in adults. UPNEEQ(R) is a once-daily eye drop shown in clinical trials to result in an average lift of one-millimeter to the upper eyelid, improving appearance and the superior visual field in patients with a functional deficit.

Patients eligible for treatment with UPNEEQ(R) include adults with droopy or low-lying eyelids, the majority of whom are females. Although the exact prevalence of acquired ptosis is unknown, RVL Pharmaceuticals believes it to be a common age-related condition.

The global medical aesthetics market revenue was estimated at $13.9 billion in 2022. It is expected to grow at a CAGR of 11%, reaching $23.4 billion by 2027. (https://ibn.fm/943Ck). The market’s expansion is believed to be due to factors such as the rising popularity of minimally invasive and non-invasive aesthetic procedures, the rising popularity of aesthetic procedures among older patients, greater accessibility to technologically advanced and user-friendly products, and the rise in demand for aesthetic treatments among the male population.

Access to UPNEEQ(R) is supported by the company’s Elevate eCommerce platform, launched in July 2023. The Elevate platform enables patient subscription ordering across channels, including HCP direct practices, HCP virtual practices, and RVL pharmacy eye care patients. The platform enhances patient retention by allowing for refills to be fulfilled by RVL Pharmacy and delivered directly to the patient’s home. At the same time, HCPs continue to share customer refills’ value. The pharmacy also offers auto-replenishment for HCPs that dispense UPNEEQ(R) through their practice.

By participating in the H.C. Wainwright conference, RVL Pharmaceuticals was able to present the benefits and significance of UPNEEQ(R) to other public companies, industry executives, business development executives, institutional investors, private equity firms, and venture capitalists.

For more information, visit the company’s website at www.RVLPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to RVLP are available in the company’s newsroom at https://ibn.fm/RVLP

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN